Oct 4, 2007 by Brian Orelli, PhDStopping the InflammationJ&J gets positive phase 3 data for its psoriasis drug.
Oct 3, 2007 by Brian Orelli, PhDBig Pharma Loves Your LiverCompanies fund a stem-cell consortium to make drugs safer.
Oct 2, 2007 by Brian Orelli, PhDAmylin's Bittersweet FDA NewsDiabetes drug moves ahead, but not as much as the company wanted.
Oct 2, 2007 by Brian Orelli, PhDPerkinElmer and ViaCell: A Bloody Good Deal?PerkinElmer buys ViaCell for $300 million.
Oct 2, 2007 by Brian Orelli, PhDRegeneron Sees Positive Phase 2 DataData from macular degeneration drug trial looks good.
Sep 28, 2007 by Brian Orelli, PhDSide Effects No Match for This Tag TeamSeven drugmakers team up to find genetic differences in patients susceptible to drugs.
Sep 28, 2007 by Brian Orelli, PhDRNAi Doesn't Kill Mice After AllAlnylam and Roche researchers discover a workaround for an RNAi problem.
Sep 28, 2007 by Brian Orelli, PhDIdenix Axes Ailing InitiativesThe company drops one of its three development areas to shore up its burn rate.
Sep 28, 2007 by Brian Orelli, PhDFree Drugs From MerckMerck gives away doses of its Gardasil vaccine.
Sep 27, 2007 by Brian Orelli, PhDForeign Invasion of the Biochip MarketA conglomerate of Japanese companies hopes to develop biochips.
Sep 27, 2007 by Brian Orelli, PhDIncyte's Double Dose of Trial NewsTwo drugs provide good results in preliminary trials.
Sep 26, 2007 by Brian Orelli, PhDSecond-Line Isn't Second BestSchering-Plough gets a positive recommendation for its hepatitis C drugs.
Sep 26, 2007 by Brian Orelli, PhD4 Platform Drugmakers to WatchPlatforms have the potential to develop multiple drugs for a company.
Sep 25, 2007 by Brian Orelli, PhDOnyx Moves AheadBayer and Onyx score a positive recommendation from an EU committee.
Sep 25, 2007 by Brian Orelli, PhDStocks and the Seven-Year ItchWhen should you re-evaluate your holdings?
Sep 25, 2007 by Brian Orelli, PhDCold HIV Vaccine Gets FrozenMerck's HIV vaccine fails in phase 2 trials.
Sep 25, 2007 by Brian Orelli, PhDNo Drugs, No RallySonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
Sep 21, 2007 by Brian Orelli, PhDSize Does MatterBioCryst announces failed phase 2 data with an excuse.
Sep 20, 2007 by Brian Orelli, PhDTeva's Disappointing Phase 2 ResultsTeva's lupus drug fails to meet its primary endpoint in its phase 2 trial.
Sep 20, 2007 by Brian Orelli, PhDWinners and Losers in Universal Health CareThey're not who you'd think.
